pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,109 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1183Endpoints903BioPharma Dive347BioSpace317Fierce Biotech301onclive165raps106globenewswire health
therapy area
allOncology7751Rare Disease1885Cardiology1770Immunology1511Hematology1328Vaccines1204Pulmonology
  • Tango and Revolution report high response rates in early pancreatic cancer combo trial
    Tango Therapeutics and Revolution Medicines tested a combination of Tango's drug vopimetostat with Revolution's daraxonrasib in an early-stage clinical trial for pancreatic cancer. The study enroll…
    STAT · 3mo agoPositive readoutPositive↗ source
  • UnitedHealthcare reduces reimbursement for lactation counseling, sparking provider backlash
    UnitedHealthcare announced a change to its payment policy for lactation counseling services. The new policy would lower or eliminate reimbursement for many providers who offer these services, prom…
    STAT · 3mo agoRegulatoryNegative↗ source
← prev
page 63 of 85
next →
73
fda recalls70
fda medwatch60
fda press38
1200
Psychiatry & CNS870
Ophthalmology502
Pain482
Endocrinology & Metabolism481
Infectious Disease444
  • Mass General launches mobile vascular clinic to treat unhoused patients and prevent amputations
    Unhoused individuals often face untreated vascular problems that can quickly lead to severe wounds and the risk of losing a limb. Limited access to regular medical care leaves many without timely i…
    STAT · 3mo agoPositive↗ source
  • ADA conference sees data presentations and police escort of members over editorial distribution
    The American Diabetes Association held its annual meeting in New Orleans, concluding three days of sessions that featured new data readouts and scientific presentations. Attendees heard updates on…
    STAT · 3mo agoNeutral↗ source
  • U.S. horses face obesity epidemic mirroring human rates
    A recent peer‑reviewed study found that about 51% of mature light‑breed horses in the United States are obese, a prevalence that ranks among the world’s highest and exceeds rates in Britain, Austra…
    STAT · 3mo agoNegative↗ source
  • Boehringer’s obesity drug cuts liver fat but lags behind competitors in weight loss
    Data from a Phase 3 trial of Boehringer Ingelheim’s weekly injectable survodutide were presented at the American Diabetes Association meeting. Patients receiving the highest dose lost about 13% of…
    STAT · 3mo agoNegative readoutNegative↗ source
  • STAT roundup highlights obesity drug competition and other ADA conference updates
    STAT's ADA in 30 Seconds newsletter offers a brief snapshot of the American Diabetes Association's annual meeting, covering a range of topics for readers. Elaine Chen notes that the market for obe…
    STAT · 3mo agoNeutral↗ source
  • Lilly presents safety data on obesity drug retatrutide, noting rare cardiac events
    Eli Lilly reported new safety and tolerability findings for its next-generation obesity therapy retatrutide at the American Diabetes Association annual meeting. In the study, 7 of the 403 particip…
    STAT · 3mo agoNegative readoutNeutral↗ source
  • Pfizer’s monthly obesity drug berobenatide shows up to 12% weight loss in mid-stage VESPER-3 study
    Detailed data from Pfizer's mid‑stage VESPER-3 trial indicate that the company’s monthly‑dosed obesity candidate, berobenatide, continues to demonstrate weight‑loss potential. The drug, originally…
    STAT · 3mo agoPositive readoutNeutral↗ source
  • Former CDC director warns that new Ebola outbreak in DRC requires massive, immediate action
    Tom Frieden, who led the U.S. CDC response to the 2014‑2016 West Africa Ebola epidemic that killed more than 11,000 people, writes about the new crisis in the Democratic Republic of the Congo. He…
    STAT · 3mo agoNegative↗ source
  • ADA conference spotlights triple hormone receptors, a monthly obesity drug and mixed outcomes
    The American Diabetes Association’s annual meeting in New Orleans featured updates on emerging diabetes therapies. Speakers highlighted research on drugs that target three hormone receptors simulta…
    STAT · 3mo agoNeutral↗ source
  • Growing Amish population poses unique public health challenges, says STAT opinion piece
    The First Opinion podcast explored how the expanding Amish community impacts public health, noting that the group may approach 2 million people in the United States by 2075. While some political fi…
    STAT · 3mo agoNeutral↗ source
  • CDC warns Ebola could swell to 20,000 cases in Central Africa without rapid containment
    The U.S. Centers for Disease Control and Prevention released a new analysis indicating that the Ebola outbreak in Central Africa could expand to as many as 20,000 cases if infected individuals are…
    STAT · 3mo agoNegative↗ source
  • HHS reclassifies 8,000 staff under Schedule F, easing firing rules and raising political pressure
    An executive order issued in late June reclassified roughly 8,000 employees of the Department of Health and Human Services. The change moves them into a “Schedule F” category that removes many civi…
    STAT · 3mo agoRegulatoryNegative↗ source
  • HHS Office of Human Research Protections faces staff shortages, jeopardizing participant safety oversight
    In 2021 the Office of Human Research Protections (OHRP) received a report of a participant suicide during a depression and mobility study at the New York State Psychiatric Institute. The incident p…
    STAT · 3mo agoRegulatoryNegative↗ source
  • ADA conference preview spotlights newer GLP-1 drugs, research funding cuts and a protest
    Elizabeth Cooney reports from the American Diabetes Association annual meeting in New Orleans, introducing the first of three STAT "ADA in 30 Seconds" newsletters. She notes the warm weather outsid…
    STAT · 3mo agoNeutral↗ source
  • US shifts Ebola treatment for exposed Americans to overseas facilities, sparking concerns over care access
    In an opinion piece, infectious‑disease physician Krutika Kuppalli reflects on her experience responding to the West Africa Ebola outbreak and the expectations that the United States would bring il…
    STAT · 3mo agoRegulatoryNegative↗ source
  • NIH senior adviser promotes MAHA strategy at ADA conference amid skeptical audience
    At the American Diabetes Association meeting in New Orleans, Richard Woychik, a senior adviser to NIH Director Jay Bhattacharya, opened his remarks by endorsing the Make America Healthy Again (MAHA…
    STAT · 3mo agoNeutral↗ source
  • RevMed’s experimental pancreatic cancer drug available via expanded access as FDA voucher program faces potential changes
    RevMed's experimental pancreatic cancer therapy daraxonrasib has not received FDA approval yet, but the company is offering it through an expanded access (compassionate use) program. Access to the…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Texas attorney general probes energy drink safety as federal research ethics office shrinks dramatically
    The Texas attorney general has opened an inquiry into the safety and marketing claims of popular energy drinks, seeking to determine whether they pose health risks or violate state consumer protect…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • FDA faces Roche blackmail claim, launches mifepristone safety study and reviews voucher program pause request
    Roche has publicly accused the United States of blackmail in a dispute that surfaced in recent FDA discussions. The company’s allegation adds tension to ongoing regulatory dialogues. The Food and…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Infinimmune appoints Srikanth Pendyala as new chief medical officer
    Infinimmune announced the addition of Srikanth Pendyala to its leadership team as chief medical officer. Pendyala comes to the role after serving in the same capacity at Stealth NewCo and Endeavor…
    STAT · 3mo agoPositive↗ source
  • Physician’s personal emergency highlights safety concerns in universal health care systems
    Nisha Narayanan, a clinical assistant professor of pediatrics who splits her practice between New York City and Edinburgh, reflects on how moving abroad reshaped her views on health care. Three we…
    STAT · 3mo agoNeutral↗ source
  • Supreme Court rules generic maker Hikma does not infringe Amarin patents, easing skinny-label lawsuits
    The U.S. Supreme Court issued a unanimous decision that Hikma Pharmaceuticals did not violate patents owned by Amarin. The high court overturned a lower court ruling that had favored the brand name…
    STAT · 3mo agoRegulatoryPositive↗ source
  • AI pioneer Jakob Uszkoreit’s Inceptive Nucleics teams with Alnylam as biotech lobby pushes Congress for DNA safeguards
    Jakob Uszkoreit, one of the architects behind the transformer model that powers ChatGPT, has turned his attention to drug development. His new venture, Inceptive Nucleics, is creating biological fo…
    STAT · 3mo agoRegulatoryNeutral↗ source